Abstract

The aim of this study was to introduce an interventional heart catheterization to close patent ductus arteriosus (PDA), ventricular septal defect (VSD), atrial septal defect (ASD), and pulmonary hypertension without complications from open heart surgery and a 3-day hospitalization period. PDA, VSD, and ASD are among the most common abnormalities associated with various complications. This case is a 3.5-year-old girl with frequent lung infections and Failure to thrive. Treatment in the first stage aims to close the PDA using Amplatzer ADO II type AGA, size 5-6 mm and ASD using Amplatzer Septal Occluder size 15 mm. The patient was discharged the next day. Six months later, a successful interventional closure of the VSD was performed using Lifetech Symmetric Amplatzer membranous size 12 mm and patient was discharged 2 days after. All these defects were corrected without open heart surgery and the need for long-term Intensive care unitsadmission.

Introduction

Congenital heart defects (CHDs) are among the most common types of congenital defects in neonates that can affect their heart structure and functions. These defects occur when the heart or blood vessels do not develop properly in the uterine [1]. Relevant treatments in these neonates are thus especially important, and with the advancement of medical care and new treatments, these neonates are living longer. The incidence of CHD varies from 4 to 50 per 1000 live births [2], and in 2017, out of ~260 000 CHD-related deaths, 180 000 occurred in neonates [3]. Patent ductus arteriosus (PDA), ventricular septal defect (VSD), and atrial septal defect (ASD) are among neonatal CHDs [1].

PDA is one of the heart disorders of newborns, which accounts for 5–10% of all CHDs and its incidence rate is 1 in 2000 births [4]. This disorder can cause intracerebral hemorrhage, necrotizing enterocolitis, and pulmonary dysplasia in neonates [5]. It also causes congestion, pulmonary edema, and disruption of oxygen exchange through by creating left-to-right shunt and increasing pulmonary artery blood flow [6]. VSD is the most common CHDs, affecting 42 cases out of every 10 000 neonates [1]. Diagnosis, determination of the size, and location of VSD by echocardiography during infancy play an important role in improving the patient prognosis. These patients are at risk of pulmonary hypertension [7]. ASD occurs when there is a failure to close the communication between the right and left atria and includes defects involving both the true septal membrane and other defects that allow communication between both atria [8]. According to Centers for Disease Control and Prevention (CDC), ASD affects 13 neonates out of every 10 000 births [1].

CHDs can be managed and treated using various methods such as catheter intervention or surgery. PDA can be closed at any time. In asymptomatic patients, it is recommended to delay treatment until 6 to 12 months to ensure lower risk. While surgical closure of ASD is effective and has a lower mortality, complications such as sternotomy and thoracotomy are unavoidable. Currently, surgery is mostly performed for ASDs with weak septa, which are difficult to close with percutaneous techniques, or failed transcatheter aortic valve replacement cases. The appropriate treatment in patients with partially closed VSD causing aortic insufficiency is surgery and resuspension of aortic valve, which should be carried out before the age of 6 to 12 months [9]. The purpose of the present study was to report a case of a two-stage interventional heart catheterization to close ASD, PDA, and VSD and control pulmonary hypertension in a 3.5-year-old girl within a 3-day hospitalization.

Case report

The studied case included a 3.5-year-old girl, weighing 11 kg, born as a singleton, which was referred to a hospital in Kerman due to frequent and recurring lung infections and Failure to thrive. Inappropriate general condition and respiratory distress were observed in the examination. Cardiac examination indicated the presence of a 3/6 systolic murmur in the left sternal border, fine rales in the peripheral part of the lung, and a bounding pulse. The chest X-ray showed presence of cardiomegaly, pulmonary vascular markings, and prominence of the pulmonary segment. Sinus rhythm, normal heart axis, large left and right ventricles were observed in the patient electrocardiography. Echocardiography also indicated the presence of situs solitus, synchronized diaphragmatic stimulation, left ventricular hypertrophy , right ventricular hypertrophy, tubular and F type PDA, secundum ASD with size 15 mm, Premembrance VSD with PG 45 mmHg and size 8.5 mm, tricuspid regurgitation 50 mmHg, and dilated pulmonary artery. Lateral ROA (root angiogram) aortogram showed PDA F type. Also, left anterior oblique injection indicates perimembranous VSD and pulmonary artery pressure 50 mmHg.

Since ASD, PDA, VSD, and pulmonary hypertension were diagnosed; it was decided to perform an interventional heart catheterization. For this purpose, PDA was closed in one step using Amplatzer ADO II type AGA, size 5–6, and then Amplatzer Septal Occluder size 15 was used to close ASD. Finally, the patient was discharged after the first stage treatment process. Six months later, a successful therapeutic interventional closure of the VSD was performed using Lifetech Symmetric Amplatzer membranous size 12 mm. Due to the lack of access to the coil, the smallest and most suitable device was used for the patient. After the treatment process, Echocardiography was used to show the position of ASD amplatzer and VSA amplatzer and there was no residual in VSD and ASD, and complications in the integrity of the aortic valve (without Aortic regurgitation or Aortic stenosis) (Fig. 1). Finally, the patient was discharged with a good general condition and no complications from open heart surgery. The treatment was successfully completed within 3 days of hospitalization. Therefore, the short length of stay in a public hospital led to a significant reduction in patient costs.

Treatment steps (A) close PDA by Amplatzer ADO II type AGA, size 5–6, (B) close ASD by Amplatzer Septal Oclotec size 15, (C) after closing PDA and ASD, D: close VSD by Amplatzer membranous, lifetec type symetric، size 12, (D) echocardiography four-chamber view after intervention.
Figure 1

Treatment steps (A) close PDA by Amplatzer ADO II type AGA, size 5–6, (B) close ASD by Amplatzer Septal Oclotec size 15, (C) after closing PDA and ASD, D: close VSD by Amplatzer membranous, lifetec type symetric، size 12, (D) echocardiography four-chamber view after intervention.

Discussion

CHDs are the most common congenital disorders associated with long-term perinatal complications and mortality. Although ASD, PDA, and VSD are each common disorders and account for ~10% of CHD cases, the combination of these defects, without other significant cardiac lesions, is rare [1, 10]. These cardiac lesions usually lead to a left-to-right intracardiac shunt and ultimately increased pulmonary blood flow. ASDs generally cause right ventricular volume overload, which may lead to right heart failure and atrial arrhythmias. On the other hand, left-to-right shunts at the atrial level or great arteries are associated with volume load in the left ventricle, and cause an increase in left ventricular end-diastolic pressure and pulmonary hypertension through a significant increase in pulmonary venous return, which, in turn, lead to symptoms of congestive heart failure, inability to grow, feeding problems, and diaphoresis [11].

In the present study, an algorithm was presented for diagnosis and simultaneous treatment of ASD, PDA, and VSD as cardiac disorders in a patient with frequent lung infections and confirmed CHD. As mentioned earlier, when the disorders were diagnosed according to the history, examinations, and echocardiography, the decision was made to implement the two-stage treatment process. It should be noted that the open heart surgery was the routine treatment for this patient at this age and low weight. For this purpose, retrograde PDA treatment was performed in the first stage, using Amplatzer ADO II type AGA, 5-6 mm without pulmonary stenosis and coarctation of the aorta. ASD closure was performed using Amplatzer Septal Occluder size 15. In the second stage within 6 months after the first procedure, the VSD was successfully closed using a Lifetech Symmetric Amplatzer membranous size 12 mm. In the study by Aishima et al., a report was presented on the successful treatment of VSD and PDA associated with pulmonary hypertension in an infant with left lung agenesis. Patch was used for VSD closure and PDA was transplanted under cardiopulmonary bypass [12]. In their study, Prada et al. successfully treated 21 babies who had various defects such as an ostium secundum ASD, PDA, and muscular VSD. Researchers suggested closing this type of disorders using Amplatzer as a safe and effective method [13]. Symptoms in most children with OS-ASD are minor and surgery is generally indicated in preschool age. OS-ASD may develop over time and early treatment is necessary in some cases. Children who have the highest risk of progressing to irreversible pulmonary hypertension need early treatment [13, 14].

Conclusion

The treatment for a patient with several concurrent congenital heart problems should be performed in the form of a cathetric intervention, if possible. This intervention will be beneficial especially for girl patients considering the shorter length of hospital stay and the absence of chest scars. Treatments of similar CHDs can be investigated in future studies and used in depending on the patient condition.

Acknowledgements

The authors would like to express their special thanks to Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Author contributions

Reza Derakhshan: concept or design of the work and acquisition.

Zahra Kamiab: analysis or interpretation of data and drafted the article.

Conflict of interest statement

None declared.

Funding

None declared.

Ethics statement

The study was approved by the Ethics Committee under the code IR.RUMS.REC.1402.138, in accordance with Helsinki Criteria.

Patient consent

Written consent was obtained from the baby’s parents to obtain a history.

References

1.

Centers for Disease Control and Prevention
.
Congenital Heart Defects (CHDs) USA: National Center on Birth Defects and Developmental Disabilities (NCBDDD)
.
2023
; ].

2.

Hoffman
JI
,
Kaplan
S
.
The incidence of congenital heart disease
.
J Am Coll Cardiol
2002
;
39
:
1890
900
.

3.

Zimmerman
MS
,
Smith
AGC
,
Sable
CA
, et al.
Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
.
Lancet Child Adolesc Health
2020
;
4
:
185
200
.

4.

Backes
CH
,
Hill
KD
,
Shelton
EL
, et al.
Patent ductus arteriosus: a contemporary perspective for the Pediatric and adult cardiac care provider
.
J Am Heart Assoc
2022
;
11
:
e025784
.

5.

Koch
J
,
Hensley
G
,
Roy
L
, et al.
Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less
.
Pediatrics
2006
;
117
:
1113
21
.

6.

Jaleel
MA
,
Rosenfeld
CR
.
Patent ductus arteriosus and intraventricular hemorrhage: a complex association
.
J Pediatr
2013
;
163
:
8
10
.

7.

Gerges
C
,
Skoro-Sajer
N
,
Lang
IM
.
Right ventricle in acute and chronic pulmonary embolism (2013 Grover Conference series)
.
Pulm Circ
2014
;
4
:
378
86
.

8.

Menillo
AM
,
Lee
LS
,
Pearson-Shaver
AL
. Atrial septal defect. In:
StatPearls [Internet]
. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 30571061.
2023
.

9.

Rao
PS
.
Management of congenital heart disease: state of the art; part I-ACYANOTIC heart defects
.
Children (Basel, Switzerland)
2019
;
6
:42.

10.

Cole
RB
,
Lawson
E
,
Newfeld
EA
, et al.
The atrial septal defect-patent ductus arteriosus complex
.
Am J Dis Child
1977
;
131
:
281
5
.

11.

Backer
CL
,
Eltayeb
O
,
Mongé
MC
, et al.
Shunt lesions part I: patent ductus arteriosus, atrial septal defect, ventricular septal defect, and atrioventricular septal defect
.
Pediatr Crit Care Med
2016
;
17
:
S302
S9
.

12.

Akishima
S
,
Honda
M
,
Kanno
M
, et al.
A successful repair of ventricular septal defect and patient ductus arteriosus associated with pulmonary hypertension in an infant with left lung agenesis
.
Nihon Kyobu Geka Gakkai
1994
;
42
:
2247
51
.

13.

Prada
F
,
Mortera
C
,
Bartrons
J
, et al.
Percutaneous treatment of atrial septal defects, muscular ventricular septal defects and patent ductus arteriosus in infants under one year of age
.
Revista Española de Cardiología (English Edition)
2009
;
62
:
1050
4
.

14.

McMahon
C
,
Feltes
T
,
Fraley
J
, et al.
Natural history of growth of secundum atrial septal defects and implications for transcatheter closure
.
Heart
2002
;
87
:
256
9
.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.